Europe Sees 2 Deaths, Multiple Cases Of COVID-Linked Syndrome In Children

A new life-threatening inflammatory syndrome associated with COVID-19 has affected 230 children in Europe and killed two so far this year, a regional health body said on Friday, as medics worldwide were told to be on alert.

The Swedish-based European Centre for Disease Prevention and Control (ECDC) said in a risk report that two children had died due to the condition: one in Britain and one in France.

The new coronavirus has so far taken its greatest toll on the elderly and those with chronic health conditions, but reports about the syndrome in children have raised fears it could pose a greater risk to the young than first through.

At a briefing in Geneva, the World Health Organisation (WHO) urged clinicians to be alert to the rare syndrome, but cautioned that links to COVID-19 were still unclear.

The condition, known as paediatric inflammatory multisystem syndrome (PIMS), shares symptoms with toxic shock and Kawasaki disease including fever, rashes, swollen glands and, in severe cases, heart inflammation.

"I call on all clinicians worldwide to work with your national authorities and WHO to be alert and better understand this syndrome in children," said WHO Director General Tedros Adhanom Ghebreyesus.

On Friday, the WHO issued a preliminary definition of the syndrome, which it said had become more frequent during the current pandemic but has also appeared in children who did not test positive for COVID-19.

The condition affected children and adolescents showing fever for more than three days, with elevated markers of inflammation.

The children also showed at least two of the following symptoms: rash or signs of inflammation around the mouth, hands or feet; shock or low blood pressure; heart problems; evidence of bleeding disorder; and acute gastrointestinal problems.

The case definition pertained to children who had contracted COVID-19 or had had likely contact with COVID-19 patients, and had no other obvious microbial cause of inflammation, it said.

"We know so far very little about this inflammatory syndrome," said WHO epidemiologist Maria Van Kerkhove.

In France, doctors said a nine-year old boy died a week ago in the southern town of Marseille after developing a syndrome akin to Kawasaki disease and being in contact with the coronavirus though not suffering its symptoms.

He was hospitalised on May 2 after scarlet fever had been diagnosed. Back home, he suffered from a severe heart ailment and was rushed back to Marseille's Timone hospital's intensive care unit, where he died.

French researchers on Thursday reported Kawasaki disease-like symptoms in 17 children admitted to a Paris hospital between April 27 and May 7, while in an average two-week period they would have expected to see only one such case.

The European Union (EU) health body ECDC added it had agreed to include the syndrome as a possible complication of COVID-19 to be reported for Europe-wide surveillance.

Research efforts should aim at determining what role the coronavirus, if any, plays in causing PIMS, it said.

The risk of PIMS in children was currently considered low, as was the risk of them contracting COVID-19, the agency said.

The US Centers for Disease Control and Prevention on Thursday issued guidance to doctors on how to recognise and report cases of the syndrome, following the reports of cases in Europe and more than 100 in the state of New York.

At its briefing, the WHO urged governments and companies to work together to develop a vaccine and treatments against COVID-19, and make distribution equitable.

"Traditional market models will not deliver at the scale needed to cover the entire globe," Tedros said.

Costa Rica's President Carlos Alvarado called at the briefing for creating a pool of patents and licences on a voluntary basis to enable fair access.

France said on Thursday the world's nations would have equal access to any vaccine developed by pharmaceuticals giant Sanofi, a day after the company's chief executive suggested Americans would likely be the first in line.